...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >Evaluation of the National Toxicology Program Report on Carcinogens
【24h】

Evaluation of the National Toxicology Program Report on Carcinogens

机译:国家致癌物毒理学计划报告评估

获取原文
获取原文并翻译 | 示例
           

摘要

This study evaluates the National Toxicology Program's Report on Carcinogens program (RoCP) and compares it with the International Agency for Research on Cancer Monographs Program (IMP). We tracked agents classified in the RoCP since 1983 as known human carcinogens (A-List), or as reasonably anticipated to be human carcinogens (B-List). The first A-list included 24 agents, and twenty-four unique agents were added in the following 28. years; twenty were listed by IMP as Group 1 (carcinogenic to humans) 7. years before their A-list appearance. Group 1 also includes 30 or more agents eligible for, but not on, the A-list. The first B-list included 98 agents, and this increased to 185. Of these, 39 are in Group 2A (probably carcinogenic), and 122 are in Group 2B (possibly carcinogenic). Only 5% of the 204 agents ever on the B-list have been upgraded to the A-list. The RoCP is severely limited because it evaluates few agents and because its B-list does not distinguish between probable and possible human carcinogens. Further, it mislabels likely non-carcinogens as reasonably anticipated to be carcinogens. If the RoCP were terminated there would be no loss or delay of information available to scientific, public health and regulatory communities.
机译:这项研究评估了美国国家毒理学计划的致癌物报告计划(RoCP),并将其与国际癌症专论研究计划(IMP)进行了比较。我们追踪了自1983年以来在RoCP中分类为已知人类致癌物(A-List)或合理预期为人类致癌物(B-List)的药物。第一个A-list包括24个代理,在随后的28年中增加了24个唯一代理。 IMP被列为第1组(对人类有致癌性),在其出现A列表之前7年被归类为IMP。第1组还包括30个或更多符合但不符合A列表资格的代理。第一个B列表包括98个代理,并且增加到185个。其中,第2A组有39个(可能致癌),第2B组有122个(可能致癌)。 B列表中的204个座席中只有5%被升级到A列表。 RoCP受到严格限制,因为它评估的药物很少,并且其B-list不能区分可能的人类致癌物。此外,如合理预期的那样,它会错误地标记可能的非致癌物。如果RoCP被终止,科学,公共卫生和监管机构所获得的信息将不会丢失或延迟。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号